12 week MRI | ||||||
---|---|---|---|---|---|---|
MRI 12 weeks (N=231) | X-ray 52 weeks (N=231) | |||||
Progression (N=46) | No progression (N=185) | p Value | Progression (N=61) | No Progression (N=170) | p Value | |
Baseline DAS28(CRP) | 5.89 (1.03) | 5.56 (1.03) | 0.06 | 5.86 (1.09) | 5.54 (1.05) | 0.05 |
Baseline CRP | 1.8 (0.8, 3.6) | 1 (0.5, 2.6) | 0.01 | 2.4 (0.8, 4.4) | 1 (0.4, 2.4) | 0.0001 |
Baseline vdHS | 11 (3.5, 27.5) | 4.5 (2, 13) | 0.004 | 8.5 (3, 24.5) | 4.5 (2, 14.5) | 0.01 |
HAQ score (week 104)* | 0.88 (0.66) | 0.64 (0.66) | 0.03 | 0.77 (0.67) | 0.65 (0.66) | 0.2 |
24 week ACR50, N(%) | 17/49 (37%) | 85/183 (47%) | 0.2 | 22/61 (36%) | 80/168 (48%) | 0.1 |
24 week MRI | ||||||
---|---|---|---|---|---|---|
MRI 24 weeks (N=238) | X-ray 52 weeks (N=238) | |||||
Progression (N=52) | No Progression (N=186) | P Value | Progression (N=62) | No progression (N=176) | P Value | |
Baseline DAS28(CRP) | 5.81 (1.13) | 5.53 (1.06) | 0.1 | 5.79 (1.10) | 5.52 (1.06) | 0.09 |
Baseline CRP | 1.8 (0.95, 3.4) | 1 (0.4, 2.5) | 0.002 | 2 (0.8, 4.2) | 1 (0.4, 2.4) | 0.001 |
Baseline vdHS | 15 (3.25, 29.8) | 4.5 (2, 13) | 0.002 | 9 (2.9, 26) | 4.5 (2, 15) | 0.01 |
HAQ score (week 104)* | 0.82 (0.65) | 0.63 (0.64) | 0.07 | 0.72 (0.65) | 0.66 (0.65) | 0.5 |
24 Week ACR50, N (%) | 14 (28%) | 86 (47%) | 0.01 | 21 (34%) | 79 (45%) | 0.1 |
Among those with available data for both outcomes.
*Adjusted for baseline HAQ.
ACR, American College of Rheumatology; CRP, C reactive protein; vdHS, van der Heijde-Sharp.